Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,485.21 +7.31 (+0.13%) Dow
39,184.48 +56.68 (+0.14%) Nasdaq
17,860.11 +54.95 (+0.31%) Bitcoin USD
62,235.54 +487.80 (+0.79%) CMC Crypto 200
1,293.87 +27.72 (+2.19%)
RPRX Dec 2024 17.500 put
| Previous close | 0.3300 |
| Open | N/A |
| Bid | 0.2000 |
| Ask | 0.9000 |
| Strike | 17.50 |
| Expiry date | 2024-12-20 |
| Day's range | 0.3300 - 0.3300 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Simply Wall St.Royalty Pharma plc (NASDAQ:RPRX) is largely controlled by institutional shareholders who own 70% of the company
Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price might be vulnerable to...
GlobeNewswireRoyalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buye
- GlobeNewswire
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in the U.S.; potential to generate royalties exceeding $150 million annually Royalty Pharma to host investor call today,
